Viveve Medical (NASDAQ:VIVE)‘s stock had its “buy” rating restated by equities research analysts at Mizuho in a research note issued on Friday. They currently have a $10.00 price target on the stock. Mizuho’s price objective indicates a potential upside of 101.61% from the stock’s previous close.
Several other brokerages have also recently issued reports on VIVE. ValuEngine cut shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Northland Securities initiated coverage on shares of Viveve Medical in a report on Friday. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, Cowen set a $11.00 target price on shares of Viveve Medical and gave the stock a “buy” rating in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $10.00.
Shares of Viveve Medical (NASDAQ VIVE) opened at $4.96 on Friday. Viveve Medical has a fifty-two week low of $3.75 and a fifty-two week high of $11.16. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72.
Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.08). Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The firm had revenue of $4.07 million for the quarter, compared to analysts’ expectations of $4.10 million. During the same quarter in the previous year, the company earned ($0.46) EPS. The company’s quarterly revenue was up 120.1% compared to the same quarter last year. research analysts expect that Viveve Medical will post -2.04 earnings per share for the current year.
A number of hedge funds have recently modified their holdings of VIVE. HighTower Advisors LLC boosted its holdings in Viveve Medical by 33.2% in the second quarter. HighTower Advisors LLC now owns 1,723,751 shares of the company’s stock worth $12,379,000 after purchasing an additional 430,033 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Viveve Medical by 135.4% in the second quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock worth $3,232,000 after purchasing an additional 258,912 shares during the last quarter. RTW Investments LP boosted its holdings in Viveve Medical by 18.8% in the third quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock worth $7,719,000 after purchasing an additional 233,585 shares during the last quarter. Manatuck Hill Partners LLC boosted its holdings in Viveve Medical by 128.6% in the second quarter. Manatuck Hill Partners LLC now owns 400,000 shares of the company’s stock worth $2,872,000 after purchasing an additional 225,000 shares during the last quarter. Finally, State Street Corp purchased a new stake in Viveve Medical in the second quarter worth approximately $1,282,000. Institutional investors own 66.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.truebluetribune.com/2018/01/07/viveve-medical-vive-earns-buy-rating-from-mizuho.html.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.